Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

Editorial comment.

Carroll PR, Whitson JM.

Urology. 2011 Apr;77(4):984-5. doi: 10.1016/j.urology.2010.10.055. No abstract available.

PMID:
21477729
2.
3.

Editorial comment on: tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.

Gallina A.

Eur Urol. 2010 Apr;57(4):639. doi: 10.1016/j.eururo.2009.03.008. Epub 2009 Mar 10. No abstract available.

PMID:
19299073
4.

Editorial comment on: tumor grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.

Yossepowitch O.

Eur Urol. 2010 Apr;57(4):639-40. doi: 10.1016/j.eururo.2009.03.009. Epub 2009 Mar 10. No abstract available.

PMID:
19299071
5.

Editorial comment.

Gupta A, Lilja H.

Urology. 2011 Apr;77(4):903-4; author reply 904. doi: 10.1016/j.urology.2010.08.045. No abstract available.

PMID:
21477718
6.

Editorial comment.

Dall'Era M.

J Urol. 2013 Jul;190(1):96. doi: 10.1016/j.juro.2013.01.112. Epub 2013 Apr 25. No abstract available.

PMID:
23624151
7.

Editorial comment.

Sundi D, Schaeffer EM.

Urology. 2014 Dec;84(6):1261-2. doi: 10.1016/j.urology.2014.06.065. Epub 2014 Oct 3. No abstract available.

PMID:
25283701
8.

Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.

Joniau S.

Eur Urol. 2008 Feb;53(2):362. Epub 2007 Nov 28. No abstract available.

PMID:
17611018
9.

Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.

Scattoni V.

Eur Urol. 2008 Feb;53(2):361. Epub 2007 Nov 28. No abstract available.

PMID:
17611014
10.
11.

Editorial comment.

Loeb S.

Urology. 2014 Aug;84(2):371-2. doi: 10.1016/j.urology.2014.02.039. Epub 2014 Jun 10. No abstract available.

PMID:
24925831
12.

Watchful waiting for prostate cancer: a review article.

Chodak GW, Warren KS.

Prostate Cancer Prostatic Dis. 2006;9(1):25-9. Review.

PMID:
16402090
13.

Expectant management of localized prostate cancer--who, what, when, where and how?

Ehdaie B.

J Urol. 2012 Sep;188(3):696-7. doi: 10.1016/j.juro.2012.06.049. Epub 2012 Jul 19. No abstract available.

PMID:
22818346
14.

[-2]pro-prostate specific antigen as an aid in prostate biopsy.

Bangma C.

J Urol. 2012 Oct;188(4):1070-1. doi: 10.1016/j.juro.2012.07.057. Epub 2012 Aug 15. No abstract available.

PMID:
22901580
15.

Editorial comment.

Chong KT.

J Urol. 2009 Oct;182(4):1348; discussion 1349. doi: 10.1016/j.juro.2009.06.155. Epub 2009 Aug 14. No abstract available.

PMID:
19683273
16.

Editorial comment.

Lin CC.

J Urol. 2009 Oct;182(4):1348; discussion 1349. doi: 10.1016/j.juro.2009.06.156. Epub 2009 Aug 14. No abstract available.

PMID:
19683264
17.

Editorial comment.

van Renterghem KM.

J Urol. 2009 Oct;182(4):1349; discussion 1349. doi: 10.1016/j.juro.2009.06.157. Epub 2009 Aug 14. No abstract available.

PMID:
19683263
18.

Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.

San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC.

J Urol. 2011 Feb;185(2):471-6. doi: 10.1016/j.juro.2010.09.115. Epub 2010 Dec 17.

PMID:
21167525
19.

Early prostate cancer--treat or watch?

Shigeta K, Naito Y, Takano T.

N Engl J Med. 2011 Aug 11;365(6):568-9. doi: 10.1056/NEJMc1106325#SA2. No abstract available.

PMID:
21830973
20.

Editorial comment.

Eyre SJ.

J Urol. 2011 Feb;185(2):488. doi: 10.1016/j.juro.2010.09.140. Epub 2010 Dec 17. No abstract available.

PMID:
21167520

Supplemental Content

Support Center